Jan 13, 2020
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO(TM) (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
Dec 19, 2019
FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris
Oct 15, 2019
Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference
May 22, 2019
FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis
Apr 30, 2019
FDA approves trade name Lexette(TM) (halobetasol propionate) foam, 0.05%
Feb 28, 2019
Ortho Dermatologics To Present New Analyses At The American Academy Of Dermatology Annual Meeting
Feb 13, 2019
Mayne Pharma launches Lexette (TM) (halobetasol propionate) foam 0.05% in the United States
Jan 17, 2019
Novel Oral Antibiotic Treatment Seysara(TM) (sarecycline) Now Available
Oct 15, 2018
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
Sep 21, 2018
Almirall acquires Allergan U.S. medical dermatology portfolio*
Aug 29, 2018
FDA Accepts Resubmission Of New Drug Application For Duobrii(TM)1 (Halobetasol Propionate And Tazarotene) Lotion
Aug 15, 2018
Ortho Dermatologics Resubmits U.S. New Drug Application For DUOBRII(TM) (halobetasol propionate and tazarotene) Lotion
Jun 18, 2018
FDA Issues Complete Response Letter For DUOBRII(TM) (Halobetasol Propionate and Tazarotene) Lotion
Apr 09, 2018
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII(TM) In The Journal of the American Academy of Dermatology
Nov 09, 2017
Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris
Nov 02, 2017
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
Sep 05, 2017
Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118